Accelerating Anticancer Drug Discovery Through AI and Robotics Integration

JW Pharmaceutical is embarking on the discovery of anticancer drug candidates by advancing its autonomous research platform, which integrates artificial intelligence (AI) and robot-based synthesis automation systems.


On June 17, JW Pharmaceutical announced that it has been selected as the lead research and development institution for the “Structure-based AI Drug Discovery Support” project, part of the Ministry of Health and Welfare’s first health and medical technology R&D program for 2026.


The purpose of this project is to enhance the platform for small molecule drug discovery by utilizing structure-based drug discovery technology, generative AI, and AI agent technologies, and to discover new drug candidates based on these advancements. The initiative targets companies that possess AI platforms for discovering small molecule chemical synthetic drug candidates.

JW Building, Gwacheon, Gyeonggi Province. JW Pharmaceutical

JW Building, Gwacheon, Gyeonggi Province. JW Pharmaceutical

View original image

In collaboration with its joint R&D partner, C&C New Drug Research Institute, JW Pharmaceutical will conduct research on discovering anticancer drug candidates over the next three years, supported by a total of KRW 2.2 billion in government funding. The core of the project is the advancement of an autonomous research platform that integrates JW Pharmaceutical’s AI drug discovery platform “JWave” with a robot-based synthesis automation system.


JWave operates based on biological and chemical big data, including genomic information of more than 500 cell lines, organoids, and disease animal models, as well as data on approximately 40,000 proprietary synthetic compounds. The platform incorporates over 20 AI models, including structure-based modeling and reinforcement learning algorithms. The synthesis automation system automates repetitive synthesis processes previously performed by researchers, thereby shortening the compound generation cycle and improving experimental accuracy.


Through this initiative, JW Pharmaceutical aims to streamline the repetitive research cycle of design, synthesis, and evaluation, as well as to increase the speed and precision of active substance screening and lead compound optimization. C&C New Drug Research Institute will verify the efficacy and drug properties of compounds derived from JWave and the synthesis automation system, and will conduct research to discover anticancer drug candidates suitable for entry into preclinical trials.



A JW Pharmaceutical representative stated, “Our selection for this project acknowledges the competitiveness of our research strategy, which synergizes our proprietary biological and chemical data, AI platform, and synthesis automation technologies. We will continue to advance the autonomous research platform in close collaboration with C&C New Drug Research Institute, and rapidly identify innovative drug candidates in disease areas with high unmet medical needs.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing